HUM Quote, Financials, Valuation and Earnings

Amedisys has a net margin of 1.63% compared to Humana's net margin of 2.88%. Humana's return on equity of 8.1% beat Amedisys's return on equity of 7.23%.

Humana has a consensus price target of $294.10, signalling upside risk potential of 15.92%. On the other hand Amedisys has an analysts' consensus of $96.86 which suggests that it could grow by 6.68%. Given that Humana has higher upside potential than Amedisys, analysts believe Humana is more attractive than Amedisys.

Humana has a beta of 0.553, which suggesting that the stock is 44.701% less volatile than S&P 500. In comparison Amedisys has a beta of 0.719, suggesting its less volatile than the S&P 500 by 28.1%.

Humana has a quarterly dividend of $0.89 per share corresponding to a yield of 1.4%. Amedisys offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Humana pays 17.32% of its earnings as a dividend. Amedisys pays out -- of its earnings as a dividend. Humana's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Humana quarterly revenues are $29.4B, which are larger than Amedisys quarterly revenues of $587.7M. Humana's net income of $480M is higher than Amedisys's net income of $16.9M. Notably, Humana's price-to-earnings ratio is 22.47x while Amedisys's PE ratio is 36.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Humana is 0.27x versus 1.29x for Amedisys. Usually stocks with elevated PS ratios are considered overvalued.

CVS Health has a net margin of 1.63% compared to Humana's net margin of 0.09%. Humana's return on equity of 8.1% beat CVS Health's return on equity of 6.68%.

Humana has a consensus price target of $294.10, signalling upside risk potential of 15.92%. On the other hand CVS Health has an analysts' consensus of $66.26 which suggests that it could grow by 47.6%. Given that CVS Health has higher upside potential than Humana, analysts believe CVS Health is more attractive than Humana.

Humana has a beta of 0.553, which suggesting that the stock is 44.701% less volatile than S&P 500. In comparison CVS Health has a beta of 0.595, suggesting its less volatile than the S&P 500 by 40.471%.

Humana has a quarterly dividend of $0.89 per share corresponding to a yield of 1.4%. CVS Health offers a yield of 5.93% to investors and pays a quarterly dividend of $0.67 per share. Humana pays 17.32% of its earnings as a dividend. CVS Health pays out 37.54% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Humana quarterly revenues are $29.4B, which are smaller than CVS Health quarterly revenues of $95.4B. Humana's net income of $480M is higher than CVS Health's net income of $87M. Notably, Humana's price-to-earnings ratio is 22.47x while CVS Health's PE ratio is 11.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Humana is 0.27x versus 0.15x for CVS Health. Usually stocks with elevated PS ratios are considered overvalued.

Option Care Health has a net margin of 1.63% compared to Humana's net margin of 4.21%. Humana's return on equity of 8.1% beat Option Care Health's return on equity of 14.65%.

Humana has a consensus price target of $294.10, signalling upside risk potential of 15.92%. On the other hand Option Care Health has an analysts' consensus of -- which suggests that it could grow by 29.79%. Given that Option Care Health has higher upside potential than Humana, analysts believe Option Care Health is more attractive than Humana.

Humana has a beta of 0.553, which suggesting that the stock is 44.701% less volatile than S&P 500. In comparison Option Care Health has a beta of 1.314, suggesting its more volatile than the S&P 500 by 31.359%.

Humana has a quarterly dividend of $0.89 per share corresponding to a yield of 1.4%. Option Care Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Humana pays 17.32% of its earnings as a dividend. Option Care Health pays out -- of its earnings as a dividend. Humana's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Humana quarterly revenues are $29.4B, which are larger than Option Care Health quarterly revenues of $1.3B. Humana's net income of $480M is higher than Option Care Health's net income of $53.9M. Notably, Humana's price-to-earnings ratio is 22.47x while Option Care Health's PE ratio is 19.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Humana is 0.27x versus 0.85x for Option Care Health. Usually stocks with elevated PS ratios are considered overvalued.

Regional Health Properties has a net margin of 1.63% compared to Humana's net margin of -23.24%. Humana's return on equity of 8.1% beat Regional Health Properties's return on equity of -489.72%.

Humana has a consensus price target of $294.10, signalling upside risk potential of 15.92%. On the other hand Regional Health Properties has an analysts' consensus of -- which suggests that it could grow by 315.68%. Given that Regional Health Properties has higher upside potential than Humana, analysts believe Regional Health Properties is more attractive than Humana.

Humana has a beta of 0.553, which suggesting that the stock is 44.701% less volatile than S&P 500. In comparison Regional Health Properties has a beta of 0.953, suggesting its less volatile than the S&P 500 by 4.677%.

Humana has a quarterly dividend of $0.89 per share corresponding to a yield of 1.4%. Regional Health Properties offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Humana pays 17.32% of its earnings as a dividend. Regional Health Properties pays out -- of its earnings as a dividend. Humana's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Humana quarterly revenues are $29.4B, which are larger than Regional Health Properties quarterly revenues of $4.2M. Humana's net income of $480M is higher than Regional Health Properties's net income of -$982K. Notably, Humana's price-to-earnings ratio is 22.47x while Regional Health Properties's PE ratio is 0.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Humana is 0.27x versus 0.17x for Regional Health Properties. Usually stocks with elevated PS ratios are considered overvalued.